

05/04/98
JC507 U.S. PTO

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Monty Krieger, Susan L. Acton and Alan M. Pearson

Serial No.: 08/765,108

Art Unit: 1812

Filed: June 19, 1995

Examiner: J. Ulm

For: CLASS B1 AND C1 SCAVENGER RECEPTORS

RECEIVED

Assistant Commissioner for Patents
Washington, D.C. 20231

MAY - 5 1998

MATRIX CUSTOMER
SERVICE CENTER

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §1.56, Applicants cite the following publications which are listed on the enclosed twelve pages of form PTO-1449. The documents marked with an asterisk (*) were cited in the parent and foreign applications. Pursuant to 37 C.F.R. 1.98(d), copies of the marked publications are not enclosed. However, copies of these documents will be made available to the Examiner upon request.

Applicants believe that no fee is required for consideration of this Information Disclosure Statement. However, if a fee is required, the Assistant Commissioner is authorized to charge any fee to Deposit Account No. 01-2507.

U.S. Patents

<u>Number</u>	<u>Issue Date</u>	<u>Patentee</u>	<u>Class/Subclass</u>
* 3,625,214	12-07-1971	Higuchi	128/160
* 4,244,946	01-13-1981	Rivier, et al.	424/177
* 4,305,872	12-15-1981	Johnston, et al.	260/112.5 R

GALL #872
1646
#11
Wattach

U.S.S.N.: 08/765,108
 Filed: June 19, 1995
 Information Disclosure Statement

* 4,316,891	02-23-1982	Guillemin, et al.	424/177
* 4,629,784	12-16-1986	Stammer	530/328
4,789,734	12-06-1988	Pierschbacher	530/395
* 4,792,525	12-20-1988	Ruoslahti, et al.	435/240.243
* 4,868,116	09-19-1989	Morgan, et al.	435/240.2
* 4,906,474	03-06-1990	Langer, et al.	424/428
* 4,925,673	05-15-1990	Stein̄er, et al.	424/455
* 4,980,286	12-25-1990	Morgan, et al.	435/172.3

Foreign Patents

<u>Number</u>	<u>Publication Date</u>	<u>Patentee</u>	<u>Country/Region</u>
WO 90/05748	05-31-1990	Massachusetts Institute of Technology	PCT
WO 93/01286	01-21-1993	Massachusetts Institute of Technology	PCT
JP, A, 05/192179			Japan
JP, A, 03/290184			Japan

Publications

* ABRAMS, et al., "Macrophages in *Drosophila* embryos and L2 cells exhibit scavenger receptor-mediated endocytosis," *Proc. Natl. Acad. USA* 89:10375-10379 (1993).

- * ABUMRAD, et al., "Cloning of a Rat Adipocyte Membrane Protein Implicated in Binding or Transport of Long-chain Fatty Acids That is Induced during Preadipocyte Differentiation," *J. Biol. Chem.* 268:17665-17668 (1993).
- * ACTON, et al., "The Collagenous Domains of Macrophage Scavenger Receptors and Complement Component C1g Mediate Their Similar, But Not Identical, Binding Specificities for Polyanionic Ligands," *J. Biol. Chem.* 268:3530-3537 (1993).
- * ACTON, et al., "Expression Cloning of SR-BI, a CD36-related Class B Scavenger Receptor," *J. Biol. Chem.* 269(33):21003-21009 (1994).
- * AGRAWAL, et al., "Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus," *Proc. Natl. Acad. Sci. USA* 85:7079-7083 (1988).
- * ARAI, et al., "Multiple Receptors for Modified Low Density Lipoproteins in Mouse Peritoneal Macrophages: Different Uptake Mechanisms for Acetylated and Oxidized Low Density Lipoproteins," *Biochem. Biophys. Res. Commun.* 159:1375-1382 (1989).
- * ARUFFO, et al., "Molecular cloning of a CD28 cDNA by a high-efficiency COS cell expression system," *Immunology* 84:8573-8577 (1987).
- * ASCH, et al., "Isolation of the Thrombospondin Membrane Receptor," *J. Clin. Invest.* 79:1054-1061 (1987).
- * ASHKENAS, et al., "Structures and high and low affinity ligand binding properties of murine type I and type II macrophage scavenger receptors," *J. Lipid Res.* 34:983-1000 (1993).
- * ASKEW, et al., "Molecular Recognition with Convergent Functional Groups, Synthetic and Structural Studies with a Model Receptor for Nucleic Acid Components," *J. Am. Chem. Soc.* 111:1082-1090 (1989).
- * BALDINI, et al., "Cloning of a Rab3 isotype predominately expressed in adipocytes," *Proc. Natl. Acad. Sci. USA* 89:5049-5052 (1992).
- * BASU, et al., "Independent Pathways for Secretion of Cholesterol and Apolipoprotein E by Macrophages," *Science* 219:871-873 (1983).

- * BICKEL, et al., "Rabbit Aortic Smooth Muscle Cells Express Inducible Macrophage Scavenger Receptor Messenger RNA That is Absent from Endothelial Cells," *J. Clin. Invest.* 90:1450-1457 (1992).
- * BLUME, et al., "Triple helix by purine-rich oligonucleotides targeted to the human dihydrofolate reductase promoter," *Nucl. Acids Res.* 20:1777-1784 (1992).
- * BROWN, et al., "Lipoprotein Metabolism in the Macrophage: Implications for Cholesterol Deposition in Atherosclerosis," *Annu. Rev. Biochem.* 52:223-261 (1983).
- * CALVO, et al., "Identification, Primary Structure, and Distribution of CLA-1, a Novel Member of the CD36/LIMPHII Gene Family," *J. Biol. Chem.* 268 (25):18929-18935 (1993).
- * CHARRON, et al., "A glucose transport protein expressed predominately in insulin-responsive tissues," *Proc. Natl. Acad. Sci. USA* 86:2535-2539 (1989).
- * CHEN, et al., "NPXY, a Sequence Often Found in Cytoplasmic Tails, is Required for Coated Pit-mediated Internalization of the Low Density Lipoprotein Receptor," *J. Biol. Chem.* 265:3116-3123 (1990).
- * CLACKSON, T., et al., "Making antibody fragments using phage display libraries," *Nature* 352:624-688 (1991).
- * COONEY, et al., "Site-Specific Oligonucleotide Binding Represses Transcription of the Human *c-myc* Gene In Vitro," *Science* 241, 456-459 (1988).
- * CROOKE, "Progress toward oligonucleotide therapeutics: pharmacodynamic properties," *FASEB J.* 7:533-539 (1993).
- * CULLEN, "Use of Eukaryotic Expression Technology in the Functional Analysis of Cloned Genes," *Methods in Enz.* 152:684-704 (1987).
- * DAUGHERTY, et al., "Polymerase chain reaction facilitates the cloning, CDR-grafting and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins," *Nucl. Acids Res.* 19:2471-2476 (1991).
- DE RIJKE, et al., "Binding characteristics of scavenger receptors on liver endothelial and Kupffer cells for modified low-density lipoproteins," *Biochem. J.* 304:69-73 (1994).

- * DOI, et al., "Charged Collagen Structure Mediates the Recognition of Negativity Charged Macromolecules by Macrophage Scavenger Receptors," *J. Biol. Chem.* 268:2126-2133 (1993).
- * DUVAL-VALENTIN, et al., "Specific inhibition of transcription by triple helix-forming oligonucleotides," *Proc. Natl. Acad. Sci. USA* 89:504-508 (1992).
- * ELLINGTON, et al., "Selection *in vitro* of single-stranded DNA molecules that fold into specific ligand-binding structures," *Nature* 355:850-852 (1992).
- * ENDEMANN, et al., "CD36 is a Receptor for Oxidized Low Density Lipoprotein," *J. Biol. Chem.* 268:11811-11816 (1993).
- * FAUST, et al., "Expression of Specific High Capacity Methylglucuronate Transport in a Chinese Hamster Ovary Cell Variant," *J. Biol. Chem.* 262:1996-2004 (1987).
- * FRASER, et al., "Divalent cation-independent macrophage adhesion inhibited by monoclonal antibody to murine scavenger receptor," *Nature* 364:343-346 (1993).
- * FREEMAN, et al., "Expression of type I and type II bovine scavenger receptors in Chinese hamster ovary cells: Lipid droplet accumulation and nonreciprocal cross competition by acetylated and oxidized low density lipoprotein," *Proc. Natl. Acad. Sci. USA* 88:4931-4935 (1991).
- FUKASAWA, et al., "Chinese Hamster Ovary Cells Expressing a Novel Type of Acetylated Low Density Lipoprotein Receptor," *J. of Biol. Chem.* 270(4):1921-1927 (1995).
- * GOLDSTEIN, et al., "Receptor-Mediated Endocytosis of Low-Density Lipoprotein in Cultured Cells," *Methods Enzymol.* 98:241-260 (1993).
- * GOLDSTEIN, et al., "Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition," *Proc. Natl. Acad. Sci. USA* 76:333-337 (1979).
- * GREENWALT, et al., "Membrane Glycoprotein CD36: A Review of Its Roles in Adherence, Signal Transduction, and Transfusion Medicine," *Blood* 80:1105-1115 (1992).
- * GREGORIADIS, G., Chapter 14. "Liposomes", Drug Carriers in Biology and Medicine pp. 287-341 (Academic Press, 1979)

* GRIGORIEV, et al., "A Triple Helix-forming Oligonucleotide-Intercalator Conjugate Acts as a Transcriptional Repressor via inhibition of NF κ B Binding of Interleukin-2 Receptor α -Regulatory Sequence," *J. Biol. Chem.* 267:3389-3395 (1992).

* HABERLAND, et al., "Two Distinct Receptors Account for Recognition of Maleyl-Albumin in Human Monocytes during Differentiation In Vitro," *J. Clin. Inves.* 77:681-689 (1986).

* HABERLAND, et al., "Role of the Maleyl-Albumin Receptor in Activation of Murine Peritoneal Macrophages In Vitro," *J. Immunol.* 142:855-862 (1989).

* HART, et al., "A *Drosophila* Gene Encoding an Epithelial Membrane Protein with Homology to CD36/LIMP II," *J. Mol. Biol.* 234:249-253 (1993).

* HERZ, et al., "Surface location and high affinity for calcium of a 500-kd liver membrane protein closely related to the LDL-receptor suggest a physiological role as lipoprotein receptor," *EMBO J.* 7:4119-4127 (1988).

* HOLT, et al., "An Oligomer Complementary to *c-myc* mRNA Inhibits Proliferation of HL-60 Promyelocytic Cells and Induces Differentiation," *Mol. Cell. Biol.* 8:963-973 (1988).

* HORIUCHI, et al., "Scavenger Function of Sinusoidal Liver Cells: Acetylated Low-density Lipoprotein is Endocytosed via a Route Distinct from Formaldehyde-treated Serum Albumin," *J. Biol. Chem.* 259:53-56 (1985).

HUANG, et al., "Membrane glycoprotein IV (CD36) is physically associated with the Fyn, Lyn, and Yes protein-tyrosine kinases in human platelets," *Proc Natl. Acad. Sci. USA* 88(17):7844-7848 (1991).

* HUNT, et al., "Characterization and sequence of a mouse hsp70 gene and its expression in mouse cell lines," *Gene* 87:199-204 (1990).

* ITAKURA, et al., "Synthesis and use of synthetic oligonucleotides," *Ann. Rev. Biochem.* 53:323-356 (1984).

* INABA, et al., "Macrophage Colony-stimulating Factor Regulates Both Activities of Neural and Acidic Cholesteryl Ester Hydrolases in Human Monocyte-derived Macrophages," *J. Clin. Invest.* 92(2):750-757 (1993).

* KABAT, et al., *Sequences of Proteins of Immunological Interest*, 4th Ed. (U.S. Dept. Health and Human Services, Bethesda, MD, 1987)

* KINGSLEY, et al., "Receptor-mediated endocytosis of low density lipoprotein: Somatic cell mutants define multiple genes required for express of surface-receptor activity," *Proc. Natl. Acad. Sci. USA* 81:5454-5458 (1984).

* KINGSLEY, et al., "DNA-Mediated Transfer of a Human Gene Required for Low-Density Lipoprotein Receptor Expression and for Multiple Golgi Processing Pathways," *Mol. Cell. Biol.* 6:2734-2737 (1986).

KOBZIK, "Lung Macrophage Uptake of Unopsonized Environmental Particles," *J. of Immunol.* 155(1):367-376 (1995).

* KODAMA, et al., "Type I macrophage scavenger receptor contains α -helical and collagen-like coiled coils," *Nature* 343:531-535 (1990).

* KRIEGER, "Molecular Flypaper and atherosclerosis: structure of the macrophage scavenger receptor," *Trends Biochem. Sci.* 17:141-146 (1992).

KRIEGER, et al., Cold Spring Harbor Symposia on Quantitative Biology Vol. LVII, 605-609 (1992).

KRIEGER, "Molecular Flypaper, Host Defense, and Atherosclerosis," *J. Biol. Chem.* 268(7):4569-4572 (1993).

* KRIEGER, et al., "Structures and Functions of Multiligand Lipoprotein Receptors: Macrophage Scavenger Receptors and LDL Receptor-Related Protein (LRP)," *J. Annu. Rev. Biochem.* 63:601-637 (1994).

* KRIEGER, et al., "Reconstituted Low Density Lipoprotein," *J. Supra. Struct.* 10:467-478 (1979).

* KRIEGER, et al., "Isolation of Chinese Hamster Cell Mutants Defective in the Receptor-mediated Endocytosis of Low Density Lipoprotein," *J. Mol. Biol.* 150:167-184 (1981).

* KRIEGER, et al., "Amphotericin B selection of mutant Chinese hamster cells with defects in the receptor-mediated endocytosis of low density lipoprotein and cholesterol biosynthesis," *Proc. Natl. Acad. Sci. USA* 80:5607-5611 (1983).

* KRIEGER, "Contemplation of Mutations in the LDL Pathway of Receptor-Mediated Endocytosis by Cocultivation of LDL Receptor-Defective Hamster Cell Mutants," *Cell* 33:413-422 (1983).

* KRIEGER, "Reconstitution of the Hydrophobic Core of Low-Density Lipoprotein," *Meth. Enzymol.* 128:608-613 (1986).

* LEWIS, et al., "Automated site-directed drug design: the concept of spacer skeletons for primary structure generation," *Proc. R. Soc. Lond.* 236, 125-140 and 141-162 (1989).

* LOWRY, et al. "Protein Measurement with the Folin Phenol Reagent," *J. Biol. Chem.* 193:265-275 (1951).

LUOMA, et al., "Expression of α_2 -Macroglobulin Receptor/Low Density Lipoprotein Receptor-related Protein and Scavenger Receptor in Human Atherosclerotic Lesions," *J. Clin. Inv.* 93(5):2014-2021 (1994).

* MAHER, et al., "Inhibition of DNA Binding Proteins by Oligonucleotide-Directed Triple Helix Formation," *Science* 245:725-730 (1989).

* MATSUMOTO, et al., "Human macrophage scavenger receptors: Primary structure expression, and localization in atherosclerotic lesions," *Proc. Natl. Acad. Sci. USA* 87:9133-9137 (1990).

* McKINALY, et al., "Rational design of antiviral agents," *Annu. Rev. Pharmacol. Toxicol.* 29:111-122 (1989).

* MERRIFIELD, "Solid Phase Peptide Synthesis I. The Synthesis of a Tetrapeptide," *J. Am. Chem. Soc.* 85:2149-2154 (1964).

* MOESTRUP, et al., "Distribution of the α_2 -macroglobulin receptor/low density lipoprotein receptor-related protein in human tissues," *Cell Tissue Res.* 269:375-382 (1992).

* MULLIGAN, "The Basic Science of Gene Therapy," *Science* 260:926-932 (1993).

* NAGELKERKE, et al., "In Vivo and in Vitro Uptake and Degradation of Acetylated Low Density Lipoprotein by Rat Liver Endothelial, Kupffer, and Parenchymal Cells," *J. Biol. Chem.*

258:12221-12227 (1983).

* NAITO, et al., "Tissue Distribution Intracellular Localization, and In Vitro Expression of Bovine Macrophage Scavenger Receptors," *Am. J. Pathol.* 139:1411-1423 (1991).

* NARANG, et al., in "Chemical Synthesis of Deoxyoligonucleotides by the Modified Triester Method," *Methods Enzymol.* 65:610-620 (1980).

* OCKENHOUSE, et al., Activation of Monocytes and Platelets by Monoclonal Antibodies or Malaria-infected Erythrocytes Binding to the CD36 Surface Receptor in vitro," *J. Clin. Invest.* 84:468-475 (1989).

* OFFENSPERGER, et. al., "In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides," *EMBO J.* 12:1257-1262 (1993).

* OQUENDO, et al., "CD36 Directly Mediates Cytoadherence of Plasmodium falciparum Parasitized Erythrocytes," *Cell* 58:95-101 (1989).

* ORSON, et al., "Oligonucleotide inhibition of IL2R α mRNA transcription by promoter region collinear triplex formation in lymphocytes," *Nucl. Acids Res.* 19:3435-3441 (1991).

* OTTNAD, et al., "Differentiation of binding sites on reconstituted hepatic scavenger receptors using oxidized low-density lipoprotein," *Biochem J.* 281:745-751 (1992).

* PEARSON, et al., "Expression cloning of dSR-CI, a class C macrophage-specific scavenger receptor from *Drosophila melanogaster*," *Proc. Natl. Acad. Sci. USA* 92:4056-4060 (1995).

* PENMAN, et al., The Type I and Type II Bovine Scavenger Receptors Expressed in Chinese Hamster Ovary Cells are Trimeric Proteins with Collagenous Triple Helical Domains Comprising Noncovalently Associated Monomers and Cys⁸³-Disulfide-linked Dimers," *J. Biol. Chem.* 266:23985-23993 (1991).

* PERRY, et al., "The Use of 3D Modeling Databases for Identifying Structure Activity Relationships," QSAR: Quantitative Structure-Activity Relationships in Drug Design pp. 189-193 (Alan R. Liss, Inc. 1989).

* PITAS, et al., "Uptake of Chemically Modified Low Density Lipoproteins In Vivo Is Mediated by Specific Endothelial Cells," *J. Cell. Biol.* 100:103-117 (1985).

* POSTEL, et al., "Evidence that a triplex-forming oligodeoxyribonucleotide binds to the c-myc promoter in HeLa cells, thereby reducing c-myc mRNA levels," *Proc. Natl. Acad. Sci. USA* 88: 8227-8231 (1991).

* PREDESCU, et al., "Binding and Transcytosis of Glycoalbumin by the Microvascular Endothelium of the Nature Myocardium: Evidence that Glycoalbumin Behaves as a Bifunctional Ligand," *J. Cell Biol.* 107:1729-1738 (1988).

* RIGOTTI, et al., "The Class B Scavenger Receptors SR-BI and CD36 are Receptors for Anionic Phospholipids," *J. Biol. Chem.* 270:1-4 (1995).

RIGOTTI, et al., "The Class B Scavenger Receptors SR-BI and CD36 Are Receptors for Anionic Phospholipids," *J. Biol. Chem.* 270(27):16221-16224 (1995).

* RIPKA, "Computers picture the perfect drug," *New Scientist* 54-57 (June 16, 1988).

* ROHRER, et al., "Coiled-coil fibrous domains mediate ligand binding by macrophage scavenger receptor type II," *Nature* 343:570-572 (1990).

* ROUVINEN, et al., "Computer-aided Drug Design," *Acta Pharmaceutica Fennica* 97:159-166 (1988).

SAMBROOK, Fritsch, and Maniatis. Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, NY, Cold Spring Harbor Laboratory Press (1989) (Table of Contents only).

* SARIN et al., "Inhibition of acquired immunodeficiency syndrome virus by oligodeoxynucleoside methylphosphonates," *Proc. Natl. Acad. Sci. USA* 85:7448-7451 (1989).

* SAVILL, et al., "Macrophage Vitronectin Receptor CD36 and Thrombospondin Cooperate in Recognition of Neutrophils Undergoing Programmed Cell Death," *Chest* 99:6S-7S (suppl) (1991).

* SCHAUB, et al., "Recombinant Human Macrophage Colony-Stimulating Factor Reduces Plasma Cholesterol and Carrageenin Granuloma Foam Cell Formation in Watanabe Heritable

Hyperlipidemic Rabbits," *Arterioscler. Thromb.* 14(1):70-76 (1994).

* SCHNITZER, et al., "Preferential Interaction of Albumin-binding Proteins, gp30 and gp18, with Conformationally Modified Albumins," *J. Biol. Chem.* 267:24544-24553 (1992).

* SCRIVER, et al., Eds., in The Metabolic and Molecular Bases of Inherited Disease, Vol. 11, 7th Ed., pp. 2033; 2060-2061, New York, McGraw Hill.

* SEGE, et al., "Characterization of a Family of Gamma-Ray-Induced CHO Mutants Demonstrates that the IdIA Locus is Diploid and Encodes the Low-Density Lipoprotein Receptor," *Mol. Cell. Biol.* 6:3268-3277 (1986).

* SEGE, et al., "Expression and regulation of human low-density lipoprotein receptors in Chinese hamster ovary cells," *Nature* 307:742-745 (1984).

* SHAW, et al., "Modified deoxyoligonucleotides stable to exonuclease degradation in serum," *Nucleic Acids Res.* 19:747-750 (1991).

* SPARROW, et al., "A Macrophage Receptor That Recognizes Oxidized Low Density Lipoprotein but Not Acetylated Low Density Lipoprotein," *J. Biol. Chem.* 264:2599-2604 (1989).

* STANTON, et al., "A Macrophage Fe Receptor for IgG Is Also a Receptor for Oxidized Low Density Lipoprotein," *J. Biol. Chem.* 267:22446-22451 (1992).

* STEINBERG, et al., "BEYOND CHOLESTEROL: Modifications of Low-Density Lipoprotein That Increase Its Atherogenicity," *N. Engl. J. Med.* 320:915-924 (1989).

* STENT, G.S., et al., Molecular Genetics, pp. 213-219 (1971).

SWIDA, et al., "Glue protein genes in *Drosophila virilis*: their organization, developmental control of transcription and specific mRNA degradation," *Development* 108(2):269-280 (1990).

* SZOSTAK, "In Vitro Genetics," *TIBS* 19:89-93 (1992).

* TANDON, et al., "Identification of Glycoprotein IV (CD36) as a Primary Receptor for Platelet-Collagen Adhesion," *J. Biol. Chem.* 264:7576-7583 (1989).


- * VANDEPOL, et al., "Clinical Applications of Recombinant Macrophage-Colony Stimulating Factor (rhM-CSF)," *Biotech Therap.* 2:231-239 (1991).
- * VEGA, et al., "Cloning Sequences and Expression of a cDNA Encoding Rat LIMP II, a Novel 74-kDa Lysosomal Membrane Protein Related to the Surface Adhesion Protein CD36," *J. Biol. Chem.* 266:16818-16824 (1991).
- * VIA, et al., "Identification and density dependent regulation of the AC-LDL Receptor in normal and transformed bovine aortic endothelial cells (BAEC)," *The FASEB J.* 6:A371, #2135 (1992).
- * VILLASCHI, et al., "Binding and Uptake of Native and Glycosylated Albumin-Gold Complexes in Perfused Rat Lungs," *Microvasc. Res.* 32:190-199 (1986).
- * WICKSTROM, et al., "Human promyelocytic leukemia HL-60 cell proliferation and *c-myc* protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted against *c-myc* mRNA," *Proc. Natl. Acad. Sci. USA* 85:1028-1032 (1988).
- * YOUNG, et al., "Triple helix formation inhibits transcription elongation in vitro," *Proc. Natl. Acad. Sci. USA* 88:10023-10026 (1991).
- * ZAMECNIK, et al., "Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous sythetic oligonucleotides complementary to viral RNA," *Proc. Natl. Acad. Sci.* 83:4143-4146 (1986).
- * ZAMECNIK, et al., "Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide," *Proc. Natl. Acad. Sci. USA* 75:280-284 (1978).
- * ZHU, et al., "Systemic Gene Expression After Intravenous DNA Delivery into Adult Mice," *Science* 261:209-211 (1993).

U.S.S.N.: 08/765,108
Filed: June 19, 1995
Information Disclosure Statement

Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicants invite the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicants are of the opinion that their claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,



Patrea L. Pabst
Reg. No. 31,284


Date: April 27, 1998
ARNALL GOLDEN & GREGORY, LLP
2800 One Atlantic Center
1201 W. Peachtree Street
Atlanta, Georgia 30309-3450
(404) 873-8794

CERTIFICATE OF MAILING (37 CFR 1.8a)

I hereby certify that this Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal

U.S.S.N.: 08/765,108
Filed: June 19, 1995
Information Disclosure Statement

Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.



Jean Hicks

Date: April 27, 1998

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	08/765,108
Filing Date	June 19, 1995
First Named Inventor	Monty Krieger, et al.
Group Art Unit	1812
Examiner Name	J. Ulm
Attorney Docket Number	MIT 6620 CIP

Sheet	1	of	12
-------	---	----	----

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner's Signature		Date Considered	
-------------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	08/765,108
Filing Date	June 19, 1995
First Named Inventor	Monty Krieger, et al.
Group Art Unit	1812
Examiner Name	J. Ulm
Attorney Docket Number	MIT 6620 CIP

Sheet 2 of 12

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
		* ABRAMS, et al., "Macrophages in <i>Drosophila</i> embryos and L2 cells exhibit scavenger receptor-mediated endocytosis," <i>Proc. Natl. Acad. Sci. USA</i> 89:10375-10379 (1993).	
		* ABUMRAD, et al., "Cloning of a Rat Adipocyte Membrane Protein Implicated in Binding or Transport of Long-chain Fatty Acids That is Induced during Preadipocyte Differentiation," <i>J. Biol. Chem.</i> 268:17665-17668 (1993).	
		* ACTON, et al., "The Collagenous Domains of Macrophage Scavenger Receptors and Complement Component C1g Mediate Their Similar, But Not Identical, Binding Specificities for Polyanionic Ligands," <i>J. Biol. Chem.</i> 268:3530-3537 (1993).	
		* ACTON, et al., "Expression Cloning of SR-BI, a CD36-related Class B Scavenger Receptor," <i>J. Biol. Chem.</i> 269(33):21003-21009 (1994).	
		* AGRAWAL, et al., "Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus," <i>Proc. Natl. Acad. Sci. USA</i> 85:7079-7083 (1988).	
		* ARAI, et al., "Multiple Receptors for Modified Low Density Lipoproteins in Mouse Peritoneal Macrophages: Different Uptake Mechanisms for Acetylated and Oxidized Low Density Lipoproteins," <i>Biochem. Biophys. Res. Commun.</i> 159:1375-1382 (1989).	
		* ARUFFO, et al., "Molecular cloning of a CD28 cDNA by a high-efficiency COS cell expression system," <i>Immunology</i> 84:8573-8577 (1987).	
		* ASCH, et al., "Isolation of the Thrombospondin Membrane Receptor," <i>J. Clin. Invest.</i> 79:1054-1061 (1987).	
		* ASHKENAS, et al., "Structures and high and low affinity ligand binding properties of murine type I and type II macrophage scavenger receptors," <i>J. Lipid Res.</i> 34:983-1000 (1993).	
		* ASKEW, et al., "Molecular Recognition with Convergent Functional Groups, Synthetic and Structural Studies with a Model Receptor for Nucleic Acid Components," <i>J. Am. Chem. Soc.</i> 111:1082-1090 (1989).	
		* BALDINI, et al., "Cloning of a Rab3 isotype predominately expressed in adipocytes," <i>Proc. Natl. Acad. Sci. USA</i> 89:5049-5052 (1992).	

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	08/765,108
Filing Date	June 19, 1995
First Named Inventor	Monty Krieger, et al.
Group Art Unit	1812
Examiner Name	J. Ulm
Attorney Docket Number	MIT 6620 CIP

Sheet 3 of 12

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
		* BASU, et al., "Independent Pathways for Secretion of Cholesterol and Apolipoprotein E by Macrophages," <i>Science</i> 219:871-873 (1983).	
		* BICKEL, et al., "Rabbit Aortic Smooth Muscle Cells Express Inducible Macrophage Scavenger Receptor Messenger RNA That is Absent from Endothelial Cells," <i>J. Clin. Invest.</i> 90:1450-1457 (1992).	
		* BLUME, et al., "Triple helix by purine-rich oligonucleotides targeted to the human dihydrofolate reductase promoter," <i>Nucl. Acids Res.</i> 20:1777-1784 (1992).	
		* BROWN, et al., "Lipoprotein Metabolism in the Macrophage: Implications for Cholesterol Deposition in Atherosclerosis," <i>Annu. Rev. Biochem.</i> 52:223-261 (1983).	
		* CALVO, et al., "Identification, Primary Structure, and Distribution of CLA-1, a Novel Member of the CD36/LIMPHII Gene Family," <i>J. Biol. Chem.</i> 268 (25):18929-18935 (1993).	
		* CHARRON, et al., "A glucose transport protein expressed predominately in insulin-responsive tissues," <i>Proc. Natl. Acad. Sci. USA</i> 86:2535-2539 (1989).	
		* CHEN, et al., "NPXY, a Sequence Often Found in Cytoplasmic Tails, is Required for Coated Pit-mediated Internalization of the Low Density Lipoprotein Receptor," <i>J. Biol. Chem.</i> 265:3116-3123 (1990).	
		* CLACKSON, T., et al., "Making antibody fragments using phage display libraries," <i>Nature</i> 352:624-688 (1991).	
		* COONEY, et al., "Site-Specific Oligonucleotide Binding Represses Transcription of the Human <i>c-myc</i> Gene In Vitro," <i>Science</i> 241, 456-459 (1988).	
		* CROOKE, "Progress toward oligonucleotide therapeutics: pharmacodynamic properties," <i>FASEB J.</i> 7:533-539 (1993).	
		* CULLEN, "Use of Eukaryotic Expression Technology in the Functional Analysis of Cloned Genes," <i>Methods in Enz.</i> 152:684-704 (1987).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	08/765,108
Filing Date	June 19, 1995
First Named Inventor	Monty Krieger, et al.
Group Art Unit	1812
Examiner Name	J. Ulm
Attorney Docket Number	MIT 6620 CIP

Sheet 4 of 12

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
		* DAUGHERTY, et al., "Polymerase chain reaction facilitates the cloning, CDR-grafting and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins," <i>Nucl. Acids Res.</i> 19:2471-2476 (1991).	
		DE RIJKE, et al., "Binding characteristics of scavenger receptors on liver endothelial and Kupffer cells for modified low-density lipoproteins," <i>Biochem. J.</i> 304:69-73 (1994).	
		* DOI, et al., "Charged Collagen Structure Mediates the Recognition of Negativity Charged Macromolecules by Macrophage Scavenger Receptors," <i>J. Biol. Chem.</i> 268:2126-2133 (1993).	
		* DUVAL-VALENTIN, et al., "Specific inhibition of transcription by triple-helix-forming oligonucleotides," <i>Proc. Natl. Acad. Sci. USA</i> 89:504-508 (1992).	
		* ELLINGTON, et al., "Selection <i>in vitro</i> of single-stranded DNA molecules that fold into specific ligand-binding structures," <i>Nature</i> 355:850-852 (1992).	
		* ENDEMANN, et al., "CD36 is a Receptor for Oxidized Low Density Lipoprotein," <i>J. Biol. Chem.</i> 268:11811-11816 (1993).	
		* FAUST, et al., "Expression of Specific High Capacity Mevalonate Transport in a Chinese Hamster Ovary Cell Variant," <i>J. Biol. Chem.</i> 262:1996-2004 (1987).	
		* FRASER, et al., "Divalent cation-independent macrophage adhesion inhibited by monoclonal antibody to murine scavenger receptor," <i>Nature</i> 364:343-346 (1993).	
		* FREEMAN, et al., "Expression of type I and type II bovine scavenger receptors in Chinese hamster ovary cells: Lipid droplet accumulation and nonreciprocal cross competition by acetylated and oxidized low density lipoprotein," <i>Proc. Natl. Acad. Sci. USA</i> 88:4931-4935 (1991).	
		FUKASAWA, et al., "Chinese Hamster Ovary Cells Expressing a Novel Type of Acetylated Low Density Lipoprotein Receptor," <i>J. of Biol. Chem.</i> 270(4):1921-1927 (1995).	
		* GOLDSTEIN, et al., "Receptor-Mediated Endocytosis of Low-Density Lipoprotein in Cultured Cells," <i>Methods Enzymol.</i> 98:241-260 (1993).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	08/765,108
Filing Date	June 19, 1995
First Named Inventor	Monty Krieger, et al.
Group Art Unit	1812
Examiner Name	J. Ulm
Attorney Docket Number	MIT 6620 CIP

Sheet 5 of 12

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
		* GOLDSTEIN, et al., "Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition," <i>Proc. Natl. Acad. Sci. USA</i> 76:333-337 (1979).	
		* GREENWALT, et al., "Membrane Glycoprotein CD36: A Review of Its Roles in Adherence, Signal Transduction, and Transfusion Medicine," <i>Blood</i> 80:1105-1115 (1992).	
		* GREGORIADIS, G., Chapter 14. "Liposomes", <i>Drug Carriers in Biology and Medicine</i> pp. 287-341 (Academic Press, 1979).	
		* GRIGORIEV, et al., "A Triple Helix-forming Oligonucleotide-Intercalator Conjugate Acts as a Transcriptional Repressor via inhibition of NF- κ B Binding of Interleukin-2 Receptor α -Regulatory Sequence," <i>J. Biol. Chem.</i> 267:3389-3395 (1992).	
		* HABERLAND, et al., "Two Distinct Receptors Account for Recognition of Maleyl-Albumin in Human Monocytes during Differentiation In Vitro," <i>J. Clin. Invest.</i> 77:681-689 (1986).	
		* HABERLAND, et al., "Role of the Maleyl-Albumin Receptor in Activation of Murine Peritoneal Macrophages In Vitro," <i>J. Immunol.</i> 142:855-862 (1989).	
		* HART, et al., "A <i>Drosophila</i> Gene Encoding an Epithelial Membrane Protein with Homology to CD36/LIMP II," <i>J. Mol. Biol.</i> 234:243-253 (1993).	
		* HERZ, et al., "Surface location and high affinity for calcium of a 500-kd liver membrane protein closely related to the LDL-receptor suggest a physiological role as lipoprotein receptor," <i>EMBO J.</i> 7:4119-4127 (1988).	
		* HOLT, et al., "An Oligomer Complementary to c-myc mRNA Inhibits Proliferation of HL-60 Promyelocytic Cells and Induces Differentiation," <i>Mol. Cell. Biol.</i> 8:963-973 (1988).	
		* HORIUCHI, et al., "Scavenger Function of Sinusoidal Liver Cells: Acetylated Low-density Lipoprotein is Endocytosed via a Route Distinct from Formaldehyde-treated Serum Albumin," <i>J. Biol. Chem.</i> 259:53-56 (1985).	
		HUANG, et al., "Membrane glycoprotein IV (CD36) is physically associated with the Fyn, Lyn, and Yes protein-tyrosine kinases in human platelets," <i>Proc Natl. Acad. Sci. USA</i> 88(17):7844-7848 (1991).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	08/765,108
Filing Date	June 19, 1995
First Named Inventor	Monty Krieger, et al.
Group Art Unit	1812
Examiner Name	J. Ulm
Attorney Docket Number	MIT 6620 CIP

Sheet 6 of 12

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
		* HUNT, et al., "Characterization and sequence of a mouse hsp70 gene and its expression in mouse cell lines," <i>Gene</i> 87:199-204 (1990).	
		* ITAKURA, et al., "Synthesis and use of synthetic oligonucleotides," <i>Ann. Rev. Biochem.</i> 53:323-356 (1984).	
		* INABA, et al., "Macrophage Colony-stimulating Factor Regulates Both Activities of Neural and Acidic Cholesteryl Ester Hydrolases in Human Monocyte-derived Macrophages," <i>J. Clin. Invest.</i> 92(2):750-757 (1993).	
		* KABAT, et al., <i>Sequences of Proteins of Immunological Interest</i> , 4th Ed. (U.S. Dept. Health and Human Services, Bethesda, MD, 1987).	
		* KINGSLEY, et al., "Receptor-mediated endocytosis of low density lipoprotein: Somatic cell mutants define multiple genes required for express of surface-receptor activity," <i>Proc. Natl. Acad. Sci. USA</i> 81:5454-5458 (1984).	
		* KINGSLEY, et al., "DNA-Mediated Transfer of a Human Gene Required for Low-Density Lipoprotein Receptor Expression and for Multiple Golgi Processing Pathways," <i>Mol. Cell. Biol.</i> 6:2734-2737 (1986).	
		KOBIK, "Lung Macrophage Uptake of Unopsonized Environmental Particles," <i>J. of Immunol.</i> 155(1):367-376 (1995).	
		* KODAMA, et al., "Type I macrophage scavenger receptor contains α -helical and collagen-like coiled coils," <i>Nature</i> 343:531-535 (1990).	
		* KRIEGER, "Molecular Flypaper and atherosclerosis: structure of the macrophage scavenger receptor," <i>Trends Biochem. Sci.</i> 17:14-146 (1992).	
		KRIEGER, et al., <i>Cold Spring Harbor Symposia on Quantitative Biology</i> Vol. LVII, 605-609 (1992).	
		KRIEGER, "Molecular Flypaper, Host Defense, and Atherosclerosis," <i>J. Biol. Chem.</i> 268(7):4569-4572 (1993).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	08/765,108
Filing Date	June 19, 1995
First Named Inventor	Monty Krieger, et al.
Group Art Unit	1812
Examiner Name	J. Ulm
Attorney Docket Number	MIT 6620 CIP

Sheet 7 of 12

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
		* KRIEGER, et al., "Structures and Functions of Multiligand Lipoprotein Receptors: Macrophage Scavenger Receptors and LDL Receptor-Related Protein (LRP)," <i>J. Annu. Rev. Biochem.</i> 63:601-637 (1994).	
		* KRIEGER, et al., "Reconstituted Low Density Lipoprotein," <i>J. Supra. Struct.</i> 10:467-478 (1979).	
		* KRIEGER, et al., "Isolation of Chinese Hamster Cell Mutants Defective in the Receptor-mediated Endocytosis of Low Density Lipoprotein," <i>J. Mol. Biol.</i> 150:167-184 (1981).	
		* KRIEGER, et al., "Amphotericin B selection of mutant Chinese hamster cells with defects in the receptor-mediated endocytosis of low density lipoprotein and cholesterol biosynthesis," <i>Proc. Natl. Acad. Sci. USA</i> 80:5607-5611 (1983).	
		* KRIEGER, "Contemplation of Mutations in the LDL Pathway of Receptor-Mediated Endocytosis by Cocultivation of LDL Receptor-Defective Hamster Cell Mutants," <i>Cell</i> 33:413-422 (1983).	
		* KRIEGER, "Reconstitution of the Hydrophobic Core of Low-Density Lipoprotein," <i>Meth. Enzymol.</i> 128:608-613 (1986).	
		* LEWIS, et al., "Automated site-directed drug design: the concept of spacer skeletons for primary structure generation," <i>Proc. R. Soc. Lond.</i> 236, 125-140 and 141-162 (1989).	
		* LOWRY, et al. "Protein Measurement with the Folin Phenol Reagent," <i>J. Biol. Chem.</i> 193:265-275 (1951).	
		LUOMA, et al., "Expression of α_2 -Macroglobulin Receptor/Low Density Lipoprotein Receptor-related Protein and Scavenger Receptor in Human Atherosclerotic Lesions," <i>J. Clin. Inv.</i> 93(5):2014-2021 (1994).	
		* MAHER, et al., "Inhibition of DNA Binding Proteins by Oligonucleotide-Directed Triple Helix Formation," <i>Science</i> 245:725-730 (1989).	
		* MATSUMOTO, et al., "Human macrophage scavenger receptors: Primary structure expression, and localization in atherosclerotic lesions," <i>Proc. Natl. Acad. Sci. USA</i> 87:9133-9137 (1990).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Sheet	8	of	12	Application Number	08/765,108
				Filing Date	June 19, 1995
				First Named Inventor	Monty Krieger, et al.
				Group Art Unit	1812
				Examiner Name	J. Ulm
				Attorney Docket Number	MIT 6620 CIP

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
		* MCKINALY, et al., "Rational design of antiviral agents," <i>Annu. Rev. Pharmacol. Toxicol.</i> 29:111-122 (1989).	
		* MERRIFIELD, "Solid Phase Peptide Synthesis I. The Synthesis of a Tetrapeptide," <i>J. Am. Chem. Soc.</i> 85:2149-2154 (1964).	
		* MOESTRUP, et al., Distribution of the α_2 -macroglobulin receptor/low density lipoprotein receptor-related protein in human tissues," <i>Cell Tissue Res.</i> 269:375-382 (1992).	
		* MULLIGAN, "The Basic Science of Gene Therapy," <i>Science</i> -260:926-932 (1993).	
		* NAGELKERKE, et al., "In Vivo and in Vitro Uptake and Degradation of Acetylated Low Density Lipoprotein by Rat Liver Endothelial, Kupffer, and Parenchymal Cells," <i>J. Biol. Chem.</i> 258:12221-12227 (1983).	
		* NAITO, et al., "Tissue Distribution Intracellular Localization, and In Vitro Expression of Bovine Macrophage Scavenger Receptors," <i>Am. J. Pathol.</i> 139:1411-1423 (1991).	
		* NARANG, et al., in "Chemical Synthesis of Deoxyoligonucleotides by the Modified Triester Method," <i>Methods Enzymol.</i> 65:610-620 (1980).	
		* OCKENHOUSE, et al., Activation of Monocytes and Platelets by Monoclonal Antibodies or Malaria-infected Erythrocytes Binding to the CD36 Surface Receptor in vitro," <i>J. Clin. Invest.</i> 84:468-475 (1989).	
		* OFFENSBERGER, et. al., "In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides," <i>EMBO J.</i> 12:1257-1262 (1993).	
		* OQUENDO, et al., "CD36 Directly Mediates Cytoadherence of Plasmodium falciparum Parasitized Erythrocytes," <i>Cell</i> 58:95-101 (1989).	
		* ORSON, et al., "Oligonucleotide inhibition of IL2R α mRNA transcription by promoter region collinear triplex formation in lymphocytes," <i>Nucl. Acids Res.</i> 19:3435-3441 (1991).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Sheet	9	of	12	Application Number	08/765,108
				Filing Date	June 19, 1995
				First Named Inventor	Monty Krieger, et al.
				Group Art Unit	1812
				Examiner Name	J. Ulm
				Attorney Docket Number	MIT 6620 CIP

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
		* OTTNAD, et al., "Differentiation of binding sites on reconstituted hepatic scavenger receptors using oxidized low-density lipoprotein," <i>Biochem J.</i> 281:745-751 (1992).	
		* PEARSON, et al., "Expression cloning of dSR-CI, a class C macrophage-specific scavenger receptor from <i>Drosophila melanogaster</i> ," <i>Proc. Natl. Acad. Sci. USA</i> 92:4056-4060 (1995).	
		* PENMAN, et al., "The Type I and Type II Bovine Scavenger Receptors Expressed in Chinese Hamster Ovary Cells are Trimeric Proteins with Collagenous Triple Helical Domains Comprising Noncovalently Associated Monomers and Cys ⁶³ -Disulfide-linked Dimers," <i>J. Biol. Chem.</i> 266:23985-23993 (1991).	
		* PERRY, et al., "The Use of 3D Modeling Databases for Identifying Structure Activity Relationships," <i>QSAR: Quantitative Structure-Activity Relationships in Drug Design</i> pp. 189-193 (Alan R. Liss, Inc. 1989).	
		* PITAS, et al., "Uptake of Chemically Modified Low Density Lipoproteins In Vivo Is Mediated by Specific Endothelial Cells," <i>J. Cell. Biol.</i> 100:103-117 (1985).	
		* POSTEL, et al., "Evidence that a triplex-forming oligodeoxyribonucleotide binds to the c-myc promoter in HeLa cells, thereby reducing c-myc mRNA levels," <i>Proc. Natl. Acad. Sci. USA</i> 88: 8227-8231 (1991).	
		* PREDESCU, et al., "Binding and Transcytosis of Glycoalbumin by the Microvascular Endothelium of the Nature Myocardium: Evidence that Glycoalbumin Behaves as a Bifunctional Ligand," <i>J. Cell Biol.</i> 107:1729-1738 (1988).	
		* RIGOTTI, et al., "The Class B Scavenger Receptors SR-BI and CD36 are Receptors for Anionic Phospholipids," <i>J. Biol. Chem.</i> 270:1-4 (1995).	
		RIGOTTI, et al., "The Class B Scavenger Receptors SR-BI and CD36 Are Receptors for Anionic Phospholipids," <i>J. Biol. Chem.</i> 270(27):16221-16224 (1995).	
		* RIPKA, "Computers picture the perfect drug," <i>New Scientist</i> 54-57 (June 16, 1988).	
		* ROHRER, et al., "Coiled-coil fibrous domains mediate ligand binding by macrophage scavenger receptor type II," <i>Nature</i> 343:570-572 (1990).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	08/765,108
Filing Date	June 19, 1995
First Named Inventor	Monty Krieger, et al.
Group Art Unit	1812
Examiner Name	J. Ulm
Attorney Docket Number	MIT 6620 CIP

Sheet 10 of 12

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
		* ROUVINEN, et al., "Computer-aided Drug Design," <i>Acta Pharmaceutica Fennica</i> 97:159-166 (1988).	
		SAMBROOK, Fritsch, and Maniatis. <u>Molecular Cloning: A Laboratory Manual</u> , Second Edition, Cold Spring Harbor, NY, Cold Spring Harbor Laboratory Press (1989) (Table of Contents only).	
		* SARIN et al., "Inhibition of acquired immunodeficiency syndrome virus by oligodeoxynucleoside methylphosphonates," <i>Proc. Natl. Acad. Sci. USA</i> 85:7448-7451 (1989).	
		* SAVILL, et al., "Macrophage Vitronectin Receptor CD36 and Thrombospondin-Cooperate in Recognition of Neutrophils Undergoing Programmed Cell Death," <i>Chest</i> 99:6S-7S (suppl) (1991).	
		* SCHAUB, et al., "Recombinant Human Macrophage Colony-Stimulating Factor Reduces Plasma Cholesterol and Carrageenan Granuloma Foam Cell Formation in Watanabe Heritable Hyperlipidemic Rabbits," <i>Arterioscler. Thromb.</i> 14(1):70-76 (1994).	
		* SCHNITZER, et al., "Preferential Interaction of Albumin-binding Proteins, gp30 and gp18, with Conformationally Modified Albumins," <i>J. Biol. Chem.</i> 267:24544-24553 (1992).	
		* SCRIVER, et al., Eds., in <u>The Metabolic and Molecular Bases of Inherited Disease</u> , Vol. 11, 7th Ed., pp. 2033; 2060-2061, New York, McGraw Hill.	
		* SEGE, et al., "Characterization of a Family of Gamma-Ray-Induced CHO Mutants Demonstrates that the Id1A Locus is Diploid and Encodes the Low-Density Lipoprotein Receptor," <i>Mol. Cell. Biol.</i> 6:3268-3277 (1986).	
		* SEGE, et al., "Expression and regulation of human low-density lipoprotein receptors in Chinese hamster ovary cells," <i>Nature</i> 307:742-745 (1984).	
		* SHAW, et al., "Modified deoxyoligonucleotides stable to exonuclease degradation in serum," <i>Nucleic Acids Res</i> 19:747-750 (1991).	
		* SPARROW, et al., "A Macrophage Receptor That Recognizes Oxidized Low Density Lipoprotein but Not Acetylated Low Density Lipoprotein," <i>J. Biol. Chem.</i> 264:2599-2604 (1989).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	08/765,108
Filing Date	June 19, 1995
First Named Inventor	Monty Krieger, et al.
Group Art Unit	1812
Examiner Name	J. Ulm
Attorney Docket Number	MIT 6620 CIP

Sheet 11 of 12

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
		* STANTON, et al., "A Macrophage Fe Receptor for IgG Is Also a Receptor for Oxidized Low Density Lipoprotein," <i>J. Biol. Chem.</i> 267:22446-22451 (1992).	
		* STEINBERG, et al., "BEYOND CHOLESTEROL: Modifications of Low-Density Lipoprotein That Increase Its Atherogenicity," <i>N. Engl. J. Med.</i> 320:915-924 (1989).	
		* STENT, G.S., et al., <i>Molecular Genetics</i> , pp. 213-219 (1971).	
		SWIDA, et al., "Glue protein genes in <i>Drosophila virilis</i> : their organization, developmental control of transcription and specific mRNA degradation," <i>Development</i> 108(2):269-280 (1990).	
		* SZOSTAK, "In Vitro Genetics," <i>TIBS</i> 19:89-93 (1992).	
		* TANDON, et al., "Identification of Glycoprotein IV (CD36) as a Primary Receptor for Platelet-Collagen Adhesion," <i>J. Biol. Chem.</i> 264:7576-7583 (1989).	
		* VANDEPOL, et al., "Clinical Applications of Recombinant Macrophage-Colony Stimulating Factor (rhM-CSF)," <i>Biotech Therap.</i> 2:231-239 (1991).	
		* VEGA, et al., "Cloning Sequences and Expression of a cDNA Encoding Rat LIMP II, a Novel 74-kDa Lysosomal Membrane Protein Related to the Surface Adhesion Protein CD36," <i>J. Biol. Chem.</i> 266:16818-16824 (1991).	
		* VIA, et al., "Identification and density dependent regulation of the AC-LDL Receptor in normal and transformed bovine aortic endothelial cells (BAEC)," <i>The FASEB J.</i> 6:A371, #2135 (1992).	
		* VILLASCHI, et al., "Binding and Uptake of Native and Glycosylated Albumin-Gold Complexes in Perfused Rat Lungs," <i>Microvasc. Res.</i> 32:190-199 (1986).	
		* WICKSTROM, et al., "Human promyelocytic leukemia HL-60 cell proliferation and <i>c-myc</i> protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted against <i>c-myc</i> mRNA," <i>Proc. Natl. Acad. Sci. USA</i> 85:1028-1032 (1988).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	08/765,108
Filing Date	June 19, 1995
First Named Inventor	Monty Krieger, et al.
Group Art Unit	1812
Examiner Name	J. Ulm
Attorney Docket Number	MIT 6620 CIP

Sheet 12 of 12

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
		* YOUNG, et al., "Triple helix formation inhibits transcription elongation in vitro," <i>Proc. Natl. Acad. Sci. USA</i> 88:10023-10026 (1991).	
		* ZAMECNIK, et al., "Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous sythetic oligonucleotides complementary to viral RNA," <i>Proc. Natl. Acad. Sci.</i> 83:4143-4146 (1986).	
		* ZAMECNIK, et al., "Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide," <i>Proc. Natl. Acad. Sci. USA</i> 75:280-284 (1978).	
		* ZHU, et al., "Systemic Gene Expression After Intravenous-DNA-Delivery into Adult Mice," <i>Science</i> 261:209-211 (1993).	

Examiner's Signature		Date Considered	
-------------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.